Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression

Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of psychiatric research 2018-11, Vol.106, p.61-68
Hauptverfasser: Zheng, Wei, Zhou, Yan-Ling, Liu, Wei-Jian, Wang, Cheng-Yu, Zhan, Yan-Ni, Li, Han-Qiu, Chen, Li-Jian, Li, Ming Ding, Ning, Yu-Ping
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 68
container_issue
container_start_page 61
container_title Journal of psychiatric research
container_volume 106
creator Zheng, Wei
Zhou, Yan-Ling
Liu, Wei-Jian
Wang, Cheng-Yu
Zhan, Yan-Ni
Li, Han-Qiu
Chen, Li-Jian
Li, Ming Ding
Ning, Yu-Ping
description Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression. Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days. After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease. Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions. •The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study.•The rapid antidepressant effects of ketamine infusion within four hours were sustained following the subsequent infusions.•The response of ketamine treatment was positively associated with the response at 24h after
doi_str_mv 10.1016/j.jpsychires.2018.09.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2116127817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022395618307349</els_id><sourcerecordid>2116127817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-e94edca99887f04f21232af71403e4614f24e4983dd411b1fcd622cace4eb3453</originalsourceid><addsrcrecordid>eNqFUU1vFSEUJUZjX1v_gmHpZkYu0JlhqY1fSROTxq4JDy6W5wyMwGvTvT9c6nvqsisuN-cj9xxCKLAeGAxvd_1uLQ_2NmQsPWcw9Uz1DMQzsoFpVB2IUT0nG8Y474S6GE7IaSk7xtjIQb4kJ4LxcRKgNuTXtVmDoyY6Oqf4HXNXMS_tX4PDtcmXNlL0Hm0tNHmacUVT0XUuFaQh1mzuMKZ9oT-wmiVEpD5lupoaMDbKfai3dB_DmmaT__hsj_NRP6R4Tl54Mxd8dXzPyM3HD98uP3dXXz99uXx31VkxytqhkuisUWqaRs-k58AFN34EyQTKAdpGolSTcE4CbMFbN3BujUWJWyEvxBl5c9Bdc_q5x1L1EorFeTYR2wWaAwzQkoGxQacD1OZUSkav1xwWkx80MP3Ygd7p_x3oxw40U7p10Kivjy777YLuH_Fv6A3w_gDAdutdwKyLbWFZdE3LVu1SeNrlN7-SoTI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2116127817</pqid></control><display><type>article</type><title>Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression</title><source>Elsevier ScienceDirect Journals</source><creator>Zheng, Wei ; Zhou, Yan-Ling ; Liu, Wei-Jian ; Wang, Cheng-Yu ; Zhan, Yan-Ni ; Li, Han-Qiu ; Chen, Li-Jian ; Li, Ming Ding ; Ning, Yu-Ping</creator><creatorcontrib>Zheng, Wei ; Zhou, Yan-Ling ; Liu, Wei-Jian ; Wang, Cheng-Yu ; Zhan, Yan-Ni ; Li, Han-Qiu ; Chen, Li-Jian ; Li, Ming Ding ; Ning, Yu-Ping</creatorcontrib><description>Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression. Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days. After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease. Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions. •The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study.•The rapid antidepressant effects of ketamine infusion within four hours were sustained following the subsequent infusions.•The response of ketamine treatment was positively associated with the response at 24h after the first infusion.</description><identifier>ISSN: 0022-3956</identifier><identifier>EISSN: 1879-1379</identifier><identifier>DOI: 10.1016/j.jpsychires.2018.09.013</identifier><identifier>PMID: 30278319</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Depression ; Efficacy ; Ketamine ; Response ; Tolerability</subject><ispartof>Journal of psychiatric research, 2018-11, Vol.106, p.61-68</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-e94edca99887f04f21232af71403e4614f24e4983dd411b1fcd622cace4eb3453</citedby><cites>FETCH-LOGICAL-c374t-e94edca99887f04f21232af71403e4614f24e4983dd411b1fcd622cace4eb3453</cites><orcidid>0000-0003-0516-332X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022395618307349$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30278319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Wei</creatorcontrib><creatorcontrib>Zhou, Yan-Ling</creatorcontrib><creatorcontrib>Liu, Wei-Jian</creatorcontrib><creatorcontrib>Wang, Cheng-Yu</creatorcontrib><creatorcontrib>Zhan, Yan-Ni</creatorcontrib><creatorcontrib>Li, Han-Qiu</creatorcontrib><creatorcontrib>Chen, Li-Jian</creatorcontrib><creatorcontrib>Li, Ming Ding</creatorcontrib><creatorcontrib>Ning, Yu-Ping</creatorcontrib><title>Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression</title><title>Journal of psychiatric research</title><addtitle>J Psychiatr Res</addtitle><description>Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression. Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days. After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease. Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions. •The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study.•The rapid antidepressant effects of ketamine infusion within four hours were sustained following the subsequent infusions.•The response of ketamine treatment was positively associated with the response at 24h after the first infusion.</description><subject>Depression</subject><subject>Efficacy</subject><subject>Ketamine</subject><subject>Response</subject><subject>Tolerability</subject><issn>0022-3956</issn><issn>1879-1379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFUU1vFSEUJUZjX1v_gmHpZkYu0JlhqY1fSROTxq4JDy6W5wyMwGvTvT9c6nvqsisuN-cj9xxCKLAeGAxvd_1uLQ_2NmQsPWcw9Uz1DMQzsoFpVB2IUT0nG8Y474S6GE7IaSk7xtjIQb4kJ4LxcRKgNuTXtVmDoyY6Oqf4HXNXMS_tX4PDtcmXNlL0Hm0tNHmacUVT0XUuFaQh1mzuMKZ9oT-wmiVEpD5lupoaMDbKfai3dB_DmmaT__hsj_NRP6R4Tl54Mxd8dXzPyM3HD98uP3dXXz99uXx31VkxytqhkuisUWqaRs-k58AFN34EyQTKAdpGolSTcE4CbMFbN3BujUWJWyEvxBl5c9Bdc_q5x1L1EorFeTYR2wWaAwzQkoGxQacD1OZUSkav1xwWkx80MP3Ygd7p_x3oxw40U7p10Kivjy777YLuH_Fv6A3w_gDAdutdwKyLbWFZdE3LVu1SeNrlN7-SoTI</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Zheng, Wei</creator><creator>Zhou, Yan-Ling</creator><creator>Liu, Wei-Jian</creator><creator>Wang, Cheng-Yu</creator><creator>Zhan, Yan-Ni</creator><creator>Li, Han-Qiu</creator><creator>Chen, Li-Jian</creator><creator>Li, Ming Ding</creator><creator>Ning, Yu-Ping</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0516-332X</orcidid></search><sort><creationdate>201811</creationdate><title>Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression</title><author>Zheng, Wei ; Zhou, Yan-Ling ; Liu, Wei-Jian ; Wang, Cheng-Yu ; Zhan, Yan-Ni ; Li, Han-Qiu ; Chen, Li-Jian ; Li, Ming Ding ; Ning, Yu-Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-e94edca99887f04f21232af71403e4614f24e4983dd411b1fcd622cace4eb3453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Depression</topic><topic>Efficacy</topic><topic>Ketamine</topic><topic>Response</topic><topic>Tolerability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Wei</creatorcontrib><creatorcontrib>Zhou, Yan-Ling</creatorcontrib><creatorcontrib>Liu, Wei-Jian</creatorcontrib><creatorcontrib>Wang, Cheng-Yu</creatorcontrib><creatorcontrib>Zhan, Yan-Ni</creatorcontrib><creatorcontrib>Li, Han-Qiu</creatorcontrib><creatorcontrib>Chen, Li-Jian</creatorcontrib><creatorcontrib>Li, Ming Ding</creatorcontrib><creatorcontrib>Ning, Yu-Ping</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of psychiatric research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Wei</au><au>Zhou, Yan-Ling</au><au>Liu, Wei-Jian</au><au>Wang, Cheng-Yu</au><au>Zhan, Yan-Ni</au><au>Li, Han-Qiu</au><au>Chen, Li-Jian</au><au>Li, Ming Ding</au><au>Ning, Yu-Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression</atitle><jtitle>Journal of psychiatric research</jtitle><addtitle>J Psychiatr Res</addtitle><date>2018-11</date><risdate>2018</risdate><volume>106</volume><spage>61</spage><epage>68</epage><pages>61-68</pages><issn>0022-3956</issn><eissn>1879-1379</eissn><abstract>Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression. Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days. After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease. Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions. •The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study.•The rapid antidepressant effects of ketamine infusion within four hours were sustained following the subsequent infusions.•The response of ketamine treatment was positively associated with the response at 24h after the first infusion.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30278319</pmid><doi>10.1016/j.jpsychires.2018.09.013</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0516-332X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-3956
ispartof Journal of psychiatric research, 2018-11, Vol.106, p.61-68
issn 0022-3956
1879-1379
language eng
recordid cdi_proquest_miscellaneous_2116127817
source Elsevier ScienceDirect Journals
subjects Depression
Efficacy
Ketamine
Response
Tolerability
title Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T15%3A53%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rapid%20and%20longer-term%20antidepressant%20effects%20of%20repeated-dose%20intravenous%20ketamine%20for%20patients%20with%20unipolar%20and%20bipolar%20depression&rft.jtitle=Journal%20of%20psychiatric%20research&rft.au=Zheng,%20Wei&rft.date=2018-11&rft.volume=106&rft.spage=61&rft.epage=68&rft.pages=61-68&rft.issn=0022-3956&rft.eissn=1879-1379&rft_id=info:doi/10.1016/j.jpsychires.2018.09.013&rft_dat=%3Cproquest_cross%3E2116127817%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2116127817&rft_id=info:pmid/30278319&rft_els_id=S0022395618307349&rfr_iscdi=true